A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

PURPOSE: Preclinical tumor models show that chemotherapy has immune modulatory properties which can be exploited in the context of immunotherapy. The purpose of this study was to determine the feasibility and immunogenicity of combinations of such an immunomodulatory chemotherapeutic agent with immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Dijkgraaf, Eveline M., Santegoets, Saskia J.A.M., Reyners, An K.L., Goedemans, Renske, Nijman, Hans W., van Poelgeest, Mariëtte I.E., van Erkel, Arien R., Smit, Vincent T.H.B.M., Daemen, Toos A.H.H., van der Hoeven, Jacobus J.M., Melief, Cornelis J.M., Welters, Marij J.P., Kroep, Judith R., van der Burg, Sjoerd H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741673/
https://www.ncbi.nlm.nih.gov/pubmed/26334096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741673/
https://www.ncbi.nlm.nih.gov/pubmed/26334096

Ejemplares similares